BridgeBio Oncology appoints Peter Lebowitz as independent director; NCG, Compensation committees; option grant

BridgeBio Oncology Therapeutics, Inc.

Board size increased to nine; Lebowitz appointed as Class I director.
Lebowitz is independent and serves on NCG and Compensation committees.
Received one-time option for 63,350 shares at $8.72/share (closing price on 3/24/2026).
Standard indemnification agreement executed covering expenses from board service.
No disclosable transactions under Reg S-K Item 404(a) involving Lebowitz.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.